Comparative study on efficacy of myo inositol over metformin in Polycystic ovary syndrome patients

D. Shivani, Pandala Sravanthi, Naga Jyothi G.


Background: Study aimed to determine the effectiveness of Myo-Inositol over Metform in women with established diagnosis of PCOS.

Method: A total of 90 women diagnosed with PCOS with Vitamin D deficiency included in the study and divided into 3 groups of 30 each. Group A received Tab. Metformin 500mg thrice daily for a period of 24 wks. Group B women received Tab. Myoinositol 2 gm twice daily for a period of 24 wks. Group C women received Tab. Metformin 500mg twice daily with Tab. Myoinositol 2 gm twice daily.

Results: After treatment, 26%, 50%, and 80% were showed regular menstrual cycles (p= 0.001).  After 6 months of treatment, there was a reduction of polycystic ovaries in 50% in group A, 80% reduction in group B, and 93.33% reduction in group C respectively. There was a significant reduction in Acne, Hirusitism, BMI, serum LH, FSH, LH/FSH ratio, free testosterone, total testosterone, serum insulin levels, total cholesterol levels were seen at the end of 24 weeks in 3 groups, but higher significance seen in group C.

Conclusion: It is thus evident that Myoinositol administration helps to improve insulin sensitivity and can be used in women with PCOS having insulin resistance. Myoinositol helps in reducing metabolic and endocrine abnormalities in PCOS patients. Myoinositol is safe, inexpensive and easily available, its addition to Metformin can contribute for normalization of the dysregulated metabolism in various tissues including ovaries, pancreas, muscle and enhance the action of Metformin in improving the clinical, biochemical features of PCOS.


Hirusitism, Myoinositol, Metformin, PCOS

Full Text:



Garg G, Kachhawa G, Ramot R, Khadgawat R, Tandon N, Sreenivas V, et al. Effect of vitamin D supplementation on insulin kinetics and cardiovascular risk factors in polycystic ovarian syndrome: a pilot study. Endocrine connections. 2015;4(2):108-16.

Rashidi B, Haghollahi F, Shariat M, Zayerii F. The effects of calcium-vitamin D and metformin on polycystic ovary syndrome: a pilot study. Taiwanese J Obstetrics and Gynecol. 2009;48(2):142-7.

Tehrani HG, Mostajeran F, Shahsavari S. The effect of calcium and vitamin D supplementation on the menstrual cycle, body mass index and hyperandrogenism state of women with a polycystic ovarian syndrome. J Res Med Sci. 2014;19(9):875-80.

Kandarakis ED, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. The J Clinical Endocrinol & Metabolism. 1999;84(11):4006-11.

Jacobs ST, Donovan D, Papadopoulos A, Sarrel P, Bilezikian JP. Vitamin D and calcium dysregulation in the polycystic ovarian syndrome. Steroids. 1999;64(6):430-5.

Hoffman, Schorge, Schaffer, Halvorson, Bradshaw, Cunningham. Williams Gynecology, 2nd edition, chapter 17: pages 460-1.

Padubidri VG, Daftary SN. Howkins and Bourne, Shaw's textbook of gynecology, 16th edition, chapter 32: pages 431-32.

Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. J Epidemiology. 2013:1-13.

Fritz MA & Speroff L, Clinical Gynecologic Endocrinology, and infertility, 8th edition, chap 12:503-6.

Genazzani AD, Battaglia C, Malavasi B, Strucchi C, Tortolani F, Gamba O. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril 2004;81(1):114-9.

Ciampelli M, Fulghesu Am, Cuccinelli F, Pavone V, Ronsisvalle E, Guido M, Caruso A, Lanzone A. Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Metabolism. 1999;48(2):167-72.

Hoffman, Schorge, Schaffer, Halvorson, Bradshaw, Cunningham. Williams Gynecology, 2nd edition, chapter 17: pages 460-62.

Hemraj. B. Chandalia .RSSDI Textbook of Diabetes mellitus, 3rd edition, chap 16:216-8.

Gilvaz S, Kumari BP. Postgraduate Gynaecology. chap 9. 2011:145-9.

Alvin C. Powers. Harrison’s principles of internal medicine, 19th edition, volume 2, chap 417: 2405-06.

Govindarajan C, Pitchaipillai R, Shanmugasundaram B, Thangam S, Arokiasamy J, Pillai MS. Myoinositol: a review of its use in patients with polycystic ovary syndrome. World Journal of Pharmacy and Pharmaceutical Sciences 2015;4(6):137-55.

Gabriella D, Chiara S, Cristina F, Marcantonio B, Francesco L G, Eugenio R, Giulio C, Luciana B, and Decio A. Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome. European J Endocrinology. 2012;166(4):703-10.

Minozzi M, Nordio M, Pajalich R. The combined therapy myo-inositol plus D-Chiro- inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients. European Review for Medical and Pharmacological Sciences. 2013; 17:537-40.

Sachdeva S. Hirsutism: evaluation and treatment. Indian J Dermatol. 2010;55(1):3.

Tan S, Vollmar N, Benson S, Sowa JP, Bechmann LP, Gerken G, Fuhrer D, Canbay A. Liver injury indicating fatty liver but not serologic NASH marker improves under metformin treatment in polycystic ovary syndrome. International J Endocrinolo. 1;2015.

Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. New England J Medic. 1998;338(26):1876-80.

Martino MZ, Luigi C, Susanna F, Gabrio Z, Moreno D, Augusto F. Efficacy of myoinositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol, 2009;25(8):508-13.

Genazzani AD, Lanzoni C, Ricchieri F, JasonniVM. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol. 2008;24(3):139-44.

Angik R, Jajoo SS, Hariharan C, Chimote A. A comparative study of metabolic and hormonal effects of myoinositol vs. metformin in women with polycystic ovary syndrome: A randomised controlled trial. Int J Reprod Contracept Obstet Gynecol. 2017;4(1):189-4.